Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lung Neoplasms × tepotinib × Clear all

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Stomach Neoplasms 1 Non-Small Cell Lung Cancer Metastatic 1 Neoplasms 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Carboplatin 153 Radiotherapy 124 Cisplatin 97 Pemetrexed 93 Docetaxel 83 Paclitaxel 79 Gemcitabine 70 Magnetic Resonance Spectroscopy 67 Erlotinib Hydrochloride 64 pembrolizumab 58 Radiosurgery 57 Bevacizumab 56 Etoposide 53 durvalumab 48 Blood Specimen Collection 46 Specimen Handling 44 Nivolumab 41 Surveys and Questionnaires 39 Drug Therapy 38 Standard of Care 30 osimertinib 29 Radiation 29 Topotecan 28 atezolizumab 27 Biopsy 27 Surgical Procedures, Operative 26 Vinorelbine 24 Irinotecan 24 Educational Status 24 Early Intervention, Educational 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05782361 2025-08-20

POTENT

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡